作者: A. Vilas-Boas , S. A. Morais , D. A. Isenberg
DOI: 10.1136/RMDOPEN-2014-000011
关键词: Drug 、 Amyloidosis 、 Monoclonal antibody 、 Immunology 、 Pathophysiology 、 Cytokine 、 Medicine 、 In patient 、 Disease 、 Belimumab
摘要: Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical presentation. Many drugs have been used to treat SLE suboptimal results, especially in patients moderate-to-severe disease. Belimumab first biological drug be approved for treatment more than 50 years. This monoclonal antibody blocks B-cell activating factor, cytokine important differentiation survival. In this review we focus on activity belimumab discuss controversies its use.